- Home
- PRZO vs PPBT Comparison
PRZO vs PPBT Comparison
Compare PRZO & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRZO
- PPBT
- Stock Information
- Founded
- PRZO 2014
- PPBT 2010
- Country
- PRZO Israel
- PPBT Israel
- Employees
- PRZO N/A
- PPBT N/A
- Industry
- PRZO
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- PRZO
- PPBT Health Care
- Exchange
- PRZO Nasdaq
- PPBT Nasdaq
- Market Cap
- PRZO 20.1M
- PPBT 6.2M
- IPO Year
- PRZO 2023
- PPBT N/A
- Fundamental
- Price
- PRZO $1.61
- PPBT $2.40
- Analyst Decision
- PRZO
- PPBT Strong Buy
- Analyst Count
- PRZO 0
- PPBT 1
- Target Price
- PRZO N/A
- PPBT $33.00
- AVG Volume (30 Days)
- PRZO 2.1M
- PPBT 20.0K
- Earning Date
- PRZO 09-02-2025
- PPBT 08-15-2025
- Dividend Yield
- PRZO N/A
- PPBT N/A
- EPS Growth
- PRZO N/A
- PPBT N/A
- EPS
- PRZO N/A
- PPBT N/A
- Revenue
- PRZO $932,154.00
- PPBT N/A
- Revenue This Year
- PRZO N/A
- PPBT N/A
- Revenue Next Year
- PRZO N/A
- PPBT N/A
- P/E Ratio
- PRZO N/A
- PPBT N/A
- Revenue Growth
- PRZO 50.22
- PPBT N/A
- 52 Week Low
- PRZO $0.49
- PPBT $2.00
- 52 Week High
- PRZO $3.16
- PPBT $13.95
- Technical
- Relative Strength Index (RSI)
- PRZO 67.69
- PPBT 47.27
- Support Level
- PRZO $1.37
- PPBT $2.35
- Resistance Level
- PRZO $1.52
- PPBT $2.58
- Average True Range (ATR)
- PRZO 0.10
- PPBT 0.12
- MACD
- PRZO 0.03
- PPBT 0.01
- Stochastic Oscillator
- PRZO 74.06
- PPBT 43.75
About PRZO ParaZero Technologies Ltd.
ParaZero Technologies Ltd is an aerospace company that is focused on drone safety systems and engaged in the business of designing, developing, and providing autonomous parachute safety systems for commercial drones, also known as unmanned aerial systems. The ParaZero SafeAir system of the company applies real-time data analytics to identify and mitigate flight risks autonomously and increase safety for bystanders while protecting the loss of expensive drones, equipment, and payloads.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.